Login/Sign Up
NUBLEXA 40MG TABLET 28'S
NUBLEXA 40MG TABLET is used to treat colorectal carcinoma. It contains Regorafenib as an active ingredient, which belongs to the class of medicines known as kinase inhibitors. It works by inhibiting the action of an enzyme (tyrosine kinase) and thus stops the abnormal growth of cancer cells. This medicine is not recommended for use in pregnant and breastfeeding mothers due to embryo-fetal toxicity.
₹32529.2*
MRP ₹36965
12% off
₹32529.2*
MRP ₹36965
12% CB
₹4435.8 cashback(12%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Whats That
NUBLEXA 40MG TABLET is an anti-cancer medicine used in the treatment of colorectal carcinoma. Colorectal cancer is a disease in which the cancer or the malignant cells grow out of control in the colon or rectum.
NUBLEXA 40MG TABLET contains Regorafenib as an active ingredient, which belongs to the class of medicines known as kinase inhibitors. It works by inhibiting the action of an enzyme (tyrosine kinase) and thus stops the abnormal growth of cancer cells.
NUBLEXA 40MG TABLET may cause certain side effects such as diarrhea, rash, tiredness, decreased appetite, nausea, weight loss, fatigue, stomach pain, loss of appetite, hoarseness, and dizziness. These side effects do not require medical attention and gradually resolve over time. NUBLEXA 40MG TABLET should be taken as advised by your doctor.
Avoid taking NUBLEXA 40MG TABLET if you are allergic to it or any other components of it. Before taking this medicine, inform your doctor if you have/had liver or kidney disease, gastrointestinal disorders, hypertension, heart problems, blood disorders, plan of any surgery, or any skin disorders. This medicine is not recommended for use in pregnant and breastfeeding mothers due to embryo-fetal toxicity.
NUBLEXA 40MG TABLET contains, Regorafenib which used in the treatment of colorectal cancer (CRC) in patients who have previously been treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. It works by stopping the action of a tyrosine kinase enzyme that causes the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body. In this way, NUBLEXA 40MG TABLET stops the body's production, spread and growth of cancerous cells.
To treat your condition effectually, continue taking NUBLEXA 40MG TABLET for the period that your doctor has prescribed. Avoid taking NUBLEXA 40MG TABLET if you are allergic to it or any other components present in it. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 18 years of age as the safety and efficacy are not established. NUBLEXA 40MG TABLET may cause hypertension, heart attack, hand-foot skin reaction, gastrointestinal perforation, haemorrhage, hepatotoxicity, and Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in some patients. Hence, inform your doctor about your complete medication and medical history before taking NUBLEXA 40MG TABLET . Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Avoid driving and operating machines, as this medicine may cause dizziness.
Drug-Drug Interactions: NUBLEXA 40MG TABLET may have interaction with strong CYP3A4 inhibitors (clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir), strong CYP3A4 inducers (carbamazepine, rifampicin, phenytoin, phenobarbitone).
Drug-Food Interactions: Avoid alcohol consumption and smoking.
Dug-Disease Interactions: Tell your doctor if you have liver or kidney disease, heart problems, GI perforation, or lung toxicity before starting the treatment.
Colorectal cancer: Also known as colon cancer (growth of cancer cells in the colon) or rectal cancer (cancer cells grow in the rectum area) is a condition in which the cancerous or the malignant cells grow out of control in the colon or rectum. Symptoms may include diarrhoea, constipation, bloody stools, change in the bowel habits, abdominal discomfort, etc.
Alcohol
Unsafe
Avoid alcohol consumption while taking NUBLEXA 40MG TABLET .
Pregnancy
Unsafe
NUBLEXA 40MG TABLET is not recommended for use in pregnancy as it may cause embryo-fetal toxicity and harm your foetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before taking NUBLEXA 40MG TABLET . You should not become pregnant while you are taking NUBLEXA 40MG TABLET and for at least two weeks after your treatment. Using effective birth control methods while on treatment with NUBLEXA 40MG TABLET is suggested.
Breast Feeding
Unsafe
NUBLEXA 40MG TABLET should not be taken if you are breastfeeding as it passes into breast milk and may harm your infant.
Driving
Unsafe
NUBLEXA 40MG TABLET may cause dizziness in some patients. Hence, do not drive, operate machinery, or engage in any activity that needs concentration until you are confident that you can do so safely while you are on treatment with NUBLEXA 40MG TABLET .
Liver
Caution
If you have a pre-existing or a history of liver problems, tell your doctor before taking this medicine. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Kidney
Caution
If you have a pre-existing or a history of kidney diseases, inform your doctor before taking NUBLEXA 40MG TABLET . Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Children
Unsafe
NUBLEXA 40MG TABLET is not recommended for use in children below 18 years of age as the safety and efficacy is not established.
Country of origin
Manufacturer/Marketer address
Product Substitutes